Company:  CTI BIOPHARMA CORP (CTIC)
Form Type:  8-K
Filing Date:  3/30/2012 
CIK:  0000891293 
Address:  3101 WESTERN AVENUE
SUITE 600
 
City, State, Zip:  SEATTLE, Washington 98121 
Telephone:  (206) 282-7100 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$0.35  
Change: 
0.005 (1.45%)  
Trade Time: 
Aug 26  
Market Cap: 
$98.99M
Trade CTIC now with

© 2016  
Description of Business
We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and health care providers. Our goal is to build a profitable company by generating income from products we develop and commercialize, either alone or with partners. We are currently concentrating our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are primarily focused on commercializing PIXUVRI in select countries in the European Union, or the E.U., for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma, or NHL, and evaluating pacritinib for the treatment of adult patients with myelofibrosis. PIXUVRI PIXUVRI is a novel aza-anthracenedione with unique structural and physiochemical properties.
Register and access this filing in:     
  FORM 8-K
    SECTION 2 FINANCIAL INFORMATION
      Item 2.02. Results of Operations and Financial Condition.
    SECTION 7 REGULATION FD
      Item 7.01. Regulation FD Disclosure.
    SECTION 9 FINANCIAL STATEMENTS AND EXHIBITS
      Item 9.01. Financial Statements and Exhibits.
    SIGNATURE
    EXHIBIT INDEX
  EXHIBIT 99.1